Please assess the completion status of the following clinical trial:

Trial Title: Phase I Safety and Immunogenicity Vaccine Trial Against HIV/AIDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Negative pregnancy test for women of childbearing potential within 3 days prior to baseline evaluation and use of an acceptable means of contraception (condom, hormonal or mechanical method) for one month prior to immunization and the duration of the study;~* Clinically asymptomatic HIV-1 infected individuals (CDC Clinical category A), as determined by two positive Enzyme-linked immunosorbent assay (ELISA) and a confirmatory Western Blot;~* Mean CD4+ T cell count \>= 400 cells/microL based on 2 separate determinations, at least 2 weeks apart, within the four weeks pre-study screening period. \[Note: If one of the two values is \< 400 the patient will be excluded. Patients ever having had a value of CD4+ T cell number \< 250 will be excluded\];~* Plasma HIV-1 viremia levels \<= 50,000 copies/mL;~* Complete blood count and differential defined as:~* Hematocrit \>= 30% for women, \>= 38% for men~* Hemoglobin \>= 9.5 g/dL~* White cell counts \>= 4,000 cells/mm3~* Total lymphocyte count \>= 1000 cells/mm3~* Platelets \>= 100,000/mm3~* Differential within institutional normal limits or approval of site physician~* Normal ALT (as defined by the range of the clinical site laboratories) and Creatinine (\<= 1.6 mg/dL);~* Normal urine dipstick with esterase and nitrite;~* Normal thyroid function;~* Availability for follow-up for planned duration of at least 12 months and willing to have further brief evaluations at 24 and 36 months;~* Signed informed consent.~Exclusion Criteria:~* History of AIDS-related opportunistic or neoplastic disease;~* History of encephalopathy, neuropathy, or unstable CNS pathology (HIV or non-HIV related);~* History of non-HIV related neoplastic diseases, autoimmune diseases, angina or cardiac arthymias, or any other clinically significant medical problems;~* Chest radiography showing evidence of active or acute cardiac or pulmonary disease;~* History of anaphylaxis or serious adverse reactions to vaccines as well as serum IgE levels exceeding 1000 U.I./mL;~* History of serious allergic reaction to any substance, requiring hospitalization or emergent medical care (e.g. Steven-Johnson syndrome, bronchospasm, or hypotension);~* Active syphilis \[NOTE. If the serology is documented to be a false positive or due to an adequately treated infection, the volunteer is eligible\];~* Active tuberculosis \[NOTE: Volunteers with a positive PPD and a normal chest X-ray showing no evidence of TB and not requiring isoniazid (INH) therapy are eligible\];~* Medical or psychiatric condition or occupational responsibilities which preclude subject compliance with the protocol. Specifically excluded are persons with psychotic disorders, major affective disorders, suicidal ideation;~* Current use of psychotrophic drugs;~* Use of antiretroviral therapy within 3 months of pre-study screening.~* Use of any experimental HIV therapy or participation in another experimental protocol within three (3) months of pre-study screening;~* Current or prior therapy with immunomodulators or immunosuppressive drugs and anticoagulant drugs within 30 days prior to study medication administration;~* Any unstable cardio-vascular disease (e.g unstable hypertensive disease needing modification or introduction of an anti-hypertensive treatment);~* Live attenuated vaccines within 60 days of study \[NOTE: Medically indicated sub-unit or killed vaccines (e.g., influenza, pneumococcal, hepatitis A and B) are not exclusionary, but should be given at least 4 weeks away from HIV immunizations\];~* Receipt of blood products or immunoglobulin in the past year;~* Prior receipt of HIV-1 vaccine in a previous HIV vaccine trial;~* Positivity for HBV antigens (HBs Ag, HBe Ag), and HCV, HTLV-I and HTLV-II antibodies;~* Positivity for HHV-8 antibodies and plasmaviremia (volunteers will be screened for anti-HHV-8 antibodies and positivity confirmed by PCR, only the individuals confirmed positive by PCR will be excluded);~* Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: OTHER): Subjects were immunized subcutaneously with Tat, 3 dosage groups (7.5, 15 or 30 microgrammi), in association with Alum as adjuvant, or with Saline + Alum, as placebo.
- B (Type: OTHER): Subjects were immunized intradermally with Tat, 3 dosage groups (7.5, 15 or 30 microgrammi), or with Saline, as placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).